financetom
Business
financetom
/
Business
/
Illumina Reports Preliminary Q4, 2024 Non-GAAP Earnings, Revenue
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Illumina Reports Preliminary Q4, 2024 Non-GAAP Earnings, Revenue
Jan 14, 2025 7:29 AM

10:09 AM EST, 01/14/2025 (MT Newswires) -- Illumina ( ILMN ) said Tuesday in a preliminary report it expects Q4 non-GAAP earnings of $0.91 to $0.93 per diluted share.

Analysts polled by FactSet expect $0.91.

The company will report its earnings Feb. 6 after the market close.

Revenue for the quarter is expected to be $1.10 billion

Analysts surveyed by FactSet expect $1.07 billion.

For fiscal 2024, the company expects non-GAAP earnings of $4.12 to $4.14 per diluted share on revenue of $4.33 billion. Two analysts polled by FactSet expect $3.36. One analyst surveyed by FactSet expects 2024 revenue of $4.33 billion.

For fiscal 2025, the company projects reported revenue between $4.28 billion and $4.40 billion, and a 10% rise in non-GAAP diluted EPS. Analysts polled by FactSet expect $4.47 billion.

Price: 152.44, Change: +8.22, Percent Change: +5.70

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Heron Therapeutics Receives FDA Approval for Zynrelef Extended-Release Solution
Heron Therapeutics Receives FDA Approval for Zynrelef Extended-Release Solution
Oct 3, 2024
09:04 AM EDT, 09/25/2024 (MT Newswires) -- Heron Therapeutics ( HRTX ) said Wednesday that the US Food and Drug Administration has approved its application for the Zynrelef extended-release solution, VAN. The company said the new VAN would replace the current vented vial spike, simplifying aseptic preparation and reducing withdrawal time to 20 to 45 seconds. It added that the...
Pennant Group Prices $108.5 Million Common Stock Offering
Pennant Group Prices $108.5 Million Common Stock Offering
Oct 3, 2024
03:52 AM EDT, 10/03/2024 (MT Newswires) -- Pennant Group ( PNTG ) said late Wednesday it priced an underwritten public offering of 3.5 million common shares at $31 per share for expected gross proceeds of $108.5 million. The company granted the underwriters a 30-day option to buy up to an additional 525,000 shares. The offering is expected to close around...
Update: US Senate Panel Reportedly Focuses on Boeing's Quality Assurance Practices
Update: US Senate Panel Reportedly Focuses on Boeing's Quality Assurance Practices
Oct 3, 2024
09:08 AM EDT, 09/25/2024 (MT Newswires) -- (Updates to add FAA statement in the fourth paragraph.) Boeing's ( BA ) quality assurance practices are the focus as the US Senate Permanent Subcommittee on Investigations found the company's workers continue to feel pressure to prioritize speed of production over quality, news outlets reported Wednesday, citing a memo from the Senate panel's...
Cintas Fiscal Q1 Earnings, Revenue Rise; Fiscal 2025 Guidance Lifted
Cintas Fiscal Q1 Earnings, Revenue Rise; Fiscal 2025 Guidance Lifted
Oct 3, 2024
09:08 AM EDT, 09/25/2024 (MT Newswires) -- Cintas ( CTAS ) reported fiscal Q1 earnings Wednesday of $1.10 per diluted share, up from $0.93 a year earlier. Analysts polled by Capital IQ expected $1. Revenue for the fiscal quarter ended Aug. 31 was $2.50 billion, compared with $2.34 billion a year earlier. Analysts surveyed by Capital IQ expected $2.49 billion....
Copyright 2023-2026 - www.financetom.com All Rights Reserved